Last reviewed · How we verify
NCT05922540
a Cohort Study of Ischemic Cerebrovascular Disease
trial testing Intravenous thrombolysis in Ischaemic Stroke in 5,000 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 November 2022 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Intravenous thrombolysis — full drug profile →
Conditions studied
- Ischaemic Stroke — all drugs for Ischaemic Stroke →
Sponsor
Xiangya Hospital of Central South University
Who can join
18 and older, any sex, with Ischaemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to establish a multicenter, large-scale, prospective cohort of patients with ischemic stroke. Various biological samples such as blood, feces, and urine are collected to identify biomarkers associated with ischemic stroke. By integrating demographic information, clinical indicators, imaging parameters, and biomarker parameters, the study aims to develop risk assessment, early warning, and prognosis prediction models. Additionally, the study aims to identify key genes and explore relevant signaling pathways related to ischemic stroke.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05922540
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intravenous thrombolysis
Trials testing the same drug.
- NCT06841965 — Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer · Phase 3 · not yet recruiting
- NCT06749834 — Intravenous Thrombolysis and NOAC · Phase 3 · recruiting
- NCT06760195 — Intra-arterial Hypothermic Magnesium Sulfate Infusion in Combination with Endovascular Thrombectomy in Acute Ischemic St · EARLY_PHASE1 · not yet recruiting
- NCT06559436 — Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke · NA · recruiting
- NCT05827042 — Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion · Phase 3 · recruiting
Other recruiting trials for Ischaemic Stroke
Currently open trials in the same condition.
- NCT07197996 — The RETRAIN Trial Phase 2 · NA · recruiting
- NCT06987643 — A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke · Phase 2 · recruiting
- NCT06940635 — Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stro · NA · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05922540 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05922540.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing